Novo Nordisk $NVO Expands Alhemo Approval in US, Boosting Haemophilia...
Key Takeaways The FDA has expanded its approval for Novo Nordisk’s Alhemo, enabling its use as a once-daily prophylactic treatment for haemophilia A and B in patients aged 12 and...